SBIR Phase II: Improved drug delivery platforms for localized and sustained drug depositio — NSF Award to NOSTOPHARMA, LLC (MD, $1
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the development of the safe and efficacious treatment for orthopedic and trauma surgery complications. This treatment includes localized and sustained drug delivery platform that will address the unmet medical
| Award title | SBIR Phase II: Improved drug delivery platforms for localized and sustained drug depositio |
|---|---|
| Award ID | 2415332 |
| Awardee | NOSTOPHARMA, LLC |
| City | POTOMAC |
| State | MD |
| Amount obligated | $1,016,000 |
| Principal investigator | EKATERINA VERT-WONG |
| Program | SBIR Phase II |
| Start date | 08/15/2024 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the development of the safe and efficacious treatment for orthopedic and trauma surgery complications. This treatment includes localized and sustained drug delivery platform that will address the unmet medical needs for orthopedic patients. The successful commercialization of this technology is also expected to spur more nanomedicine and nanofabrication research for the medical field. Th |
| Source | NSF Awards |
$799/mo
Try NSFGrants →